Which has better earnings & valuation, MRNA or JNJ?

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 9.63 -$2.82B -$8.15 N/A Johnson & Johnson $96.36B 5.62 $26.80B $8.65 26.03

Is MRNA or JNJ more profitable?

Johnson & Johnson has a net margin of 21.83% compared to Moderna's net margin of -143.55%. Johnson & Johnson's return on equity of 32.60% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Johnson & Johnson 21.83% 32.60% 13.29%

Does the media prefer MRNA or JNJ?

In the previous week, Johnson & Johnson had 96 more articles in the media than Moderna. MarketBeat recorded 101 mentions for Johnson & Johnson and 5 mentions for Moderna. Johnson & Johnson's average media sentiment score of 1.08 beat Moderna's score of 0.32 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Johnson & Johnson 67 Very Positive mention(s) 13 Positive mention(s) 13 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive

Which has stronger earnings and valuation, JNJ or NVAX?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $96.36B 5.62 $26.80B $8.65 26.03 Novavax $596.34M 3.02 $440.30M -$0.58 N/A

Is JNJ or NVAX more profitable?

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 21.83% 32.60% 13.29% Novavax -14.73% -14.82% 1.23%

Does the media favor JNJ or NVAX?

In the previous week, Johnson & Johnson had 84 more articles in the media than Novavax. MarketBeat recorded 101 mentions for Johnson & Johnson and 17 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.08 beat Novavax's score of 0.70 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 67 Very Positive mention(s) 13 Positive mention(s) 13 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive Novavax 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation and earnings, JNJ or ABBV?

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $96.36B 5.62 $26.80B $8.65 26.03 AbbVie $61.16B 6.29 $4.23B $2.03 107.30

Is JNJ or ABBV more profitable?

Johnson & Johnson has a net margin of 21.83% compared to AbbVie's net margin of 5.79%. Johnson & Johnson's return on equity of 32.60% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 21.83% 32.60% 13.29% AbbVie 5.79% -576.45% 13.39%

Does the media favor JNJ or ABBV?

In the previous week, Johnson & Johnson had 46 more articles in the media than AbbVie. MarketBeat recorded 101 mentions for Johnson & Johnson and 55 mentions for AbbVie. Johnson & Johnson's average media sentiment score of 1.08 beat AbbVie's score of 1.06 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 67 Very Positive mention(s) 13 Positive mention(s) 13 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive AbbVie 37 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation & earnings, JNJ or AZN?

Johnson & Johnson has higher revenue and earnings than Astrazeneca. Johnson & Johnson is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $96.36B 5.62 $26.80B $8.65 26.03 Astrazeneca $60.44B 4.76 $10.23B $6.66 27.85

Does the media prefer JNJ or AZN?

In the previous week, Johnson & Johnson had 95 more articles in the media than Astrazeneca. MarketBeat recorded 101 mentions for Johnson & Johnson and 6 mentions for Astrazeneca. Johnson & Johnson's average media sentiment score of 1.08 beat Astrazeneca's score of 0.43 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 67 Very Positive mention(s) 13 Positive mention(s) 13 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive Astrazeneca 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer BRK.B or JNJ?

In the previous week, Johnson & Johnson had 86 more articles in the media than Berkshire Hathaway. MarketBeat recorded 101 mentions for Johnson & Johnson and 15 mentions for Berkshire Hathaway. Johnson & Johnson's average media sentiment score of 1.08 beat Berkshire Hathaway's score of 0.42 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Berkshire Hathaway 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Johnson & Johnson 67 Very Positive mention(s) 13 Positive mention(s) 13 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive

Johnson & Johnson (JNJ) Competitors

$225.16 -5.64 (-2.44%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$225.42 +0.25 (+0.11%)

As of 05/29/2026 07:59 PM Eastern

Compare

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

Should you buy Johnson & Johnson stock or one of its competitors? MarketBeat compares Johnson & Johnson with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Johnson & Johnson include Moderna (MRNA), Novavax (NVAX), AbbVie (ABBV), Astrazeneca (AZN), and Berkshire Hathaway (BRK.B).

How does Johnson & Johnson compare to Moderna?

Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Johnson & Johnson had 96 more articles in the media than Moderna. MarketBeat recorded 101 mentions for Johnson & Johnson and 5 mentions for Moderna. Johnson & Johnson's average media sentiment score of 1.08 beat Moderna's score of 0.32 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Johnson & Johnson	67 Very Positive mention(s)	13 Positive mention(s)	13 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Johnson & Johnson has a net margin of 21.83% compared to Moderna's net margin of -143.55%. Johnson & Johnson's return on equity of 32.60% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Johnson & Johnson	21.83%	32.60%	13.29%

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.63	-$2.82B	-$8.15	N/A
Johnson & Johnson	$96.36B	5.62	$26.80B	$8.65	26.03

Moderna currently has a consensus price target of $35.73, suggesting a potential downside of 24.28%. Johnson & Johnson has a consensus price target of $253.04, suggesting a potential upside of 12.38%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

Summary

Johnson & Johnson beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to Novavax?

Johnson & Johnson (NYSE:JNJ) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Johnson & Johnson currently has a consensus target price of $253.04, indicating a potential upside of 12.38%. Novavax has a consensus target price of $12.13, indicating a potential upside of 10.53%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts clearly believe Johnson & Johnson is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$96.36B	5.62	$26.80B	$8.65	26.03
Novavax	$596.34M	3.02	$440.30M	-$0.58	N/A

In the previous week, Johnson & Johnson had 84 more articles in the media than Novavax. MarketBeat recorded 101 mentions for Johnson & Johnson and 17 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.08 beat Novavax's score of 0.70 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	67 Very Positive mention(s)	13 Positive mention(s)	13 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Novavax	-14.73%	-14.82%	1.23%

Johnson & Johnson has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Novavax has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 1.0% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Novavax on 14 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to AbbVie?

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Johnson & Johnson had 46 more articles in the media than AbbVie. MarketBeat recorded 101 mentions for Johnson & Johnson and 55 mentions for AbbVie. Johnson & Johnson's average media sentiment score of 1.08 beat AbbVie's score of 1.06 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	67 Very Positive mention(s)	13 Positive mention(s)	13 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive
AbbVie	37 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Johnson & Johnson currently has a consensus price target of $253.04, indicating a potential upside of 12.38%. AbbVie has a consensus price target of $253.43, indicating a potential upside of 16.34%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Johnson & Johnson has a net margin of 21.83% compared to AbbVie's net margin of 5.79%. Johnson & Johnson's return on equity of 32.60% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
AbbVie	5.79%	-576.45%	13.39%

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.2%. Johnson & Johnson pays out 62.0% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 64 consecutive years and AbbVie has increased its dividend for 53 consecutive years.

Johnson & Johnson has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$96.36B	5.62	$26.80B	$8.65	26.03
AbbVie	$61.16B	6.29	$4.23B	$2.03	107.30

Summary

Johnson & Johnson beats AbbVie on 11 of the 20 factors compared between the two stocks.

How does Johnson & Johnson compare to Astrazeneca?

Johnson & Johnson (NYSE:JNJ) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Johnson & Johnson has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

Johnson & Johnson has a net margin of 21.83% compared to Astrazeneca's net margin of 17.19%. Johnson & Johnson's return on equity of 32.60% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Astrazeneca	17.19%	30.86%	12.68%

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.4%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.3%. Johnson & Johnson pays out 62.0% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 64 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Johnson & Johnson has higher revenue and earnings than Astrazeneca. Johnson & Johnson is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$96.36B	5.62	$26.80B	$8.65	26.03
Astrazeneca	$60.44B	4.76	$10.23B	$6.66	27.85

In the previous week, Johnson & Johnson had 95 more articles in the media than Astrazeneca. MarketBeat recorded 101 mentions for Johnson & Johnson and 6 mentions for Astrazeneca. Johnson & Johnson's average media sentiment score of 1.08 beat Astrazeneca's score of 0.43 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	67 Very Positive mention(s)	13 Positive mention(s)	13 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive
Astrazeneca	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Johnson & Johnson currently has a consensus price target of $253.04, indicating a potential upside of 12.38%. Astrazeneca has a consensus price target of $205.33, indicating a potential upside of 10.69%. Given Johnson & Johnson's higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Johnson & Johnson beats Astrazeneca on 17 of the 19 factors compared between the two stocks.

How does Johnson & Johnson compare to Berkshire Hathaway?

Berkshire Hathaway (NYSE:BRK.B) and Johnson & Johnson (NYSE:JNJ) are related large-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Berkshire Hathaway presently has a consensus target price of $524.50, suggesting a potential upside of 10.51%. Johnson & Johnson has a consensus target price of $253.04, suggesting a potential upside of 12.38%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Berkshire Hathaway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Berkshire Hathaway	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

39.3% of Berkshire Hathaway shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 6.1% of Berkshire Hathaway shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Johnson & Johnson had 86 more articles in the media than Berkshire Hathaway. MarketBeat recorded 101 mentions for Johnson & Johnson and 15 mentions for Berkshire Hathaway. Johnson & Johnson's average media sentiment score of 1.08 beat Berkshire Hathaway's score of 0.42 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Berkshire Hathaway	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	67 Very Positive mention(s)	13 Positive mention(s)	13 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive

Johnson & Johnson has a net margin of 21.83% compared to Berkshire Hathaway's net margin of 19.31%. Johnson & Johnson's return on equity of 32.60% beat Berkshire Hathaway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Berkshire Hathaway	19.31%	6.55%	3.80%
Johnson & Johnson	21.83%	32.60%	13.29%

Berkshire Hathaway has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Berkshire Hathaway has higher revenue and earnings than Johnson & Johnson. Berkshire Hathaway is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Berkshire Hathaway	$371.44B	2.76	$66.97B	$33.59	14.13
Johnson & Johnson	$96.36B	5.62	$26.80B	$8.65	26.03

Summary

Johnson & Johnson beats Berkshire Hathaway on 11 of the 16 factors compared between the two stocks.

Get Johnson & Johnson News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JNJ vs. The Competition

Export

Metric	Johnson & Johnson	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$542.42B	$222.46B	$5.96B	$22.74B
Dividend Yield	2.32%	2.76%	2.69%	4.08%
P/E Ratio	26.03	27.39	21.63	30.62
Price / Sales	5.62	4.91	626.55	15.47
Price / Cash	15.96	13.10	43.22	25.14
Price / Book	6.68	7.30	10.55	4.79
Net Income	$26.80B	$11.61B	$3.56B	$1.07B
7 Day Performance	-4.05%	-1.32%	2.85%	1.14%
1 Month Performance	-2.16%	1.71%	4.59%	1.26%
1 Year Performance	45.27%	22.60%	37.62%	28.06%

Johnson & Johnson Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JNJ Johnson & Johnson	4.4866 of 5 stars	$225.16 -2.4%	$253.04 +12.4%	+45.3%	$542.42B	$94.19B	26.03	138,200	Trending News Ex-Dividend
MRNA Moderna	1.4911 of 5 stars	$47.54 +1.4%	$35.73 -24.8%	+77.7%	$18.86B	$1.94B	N/A	4,700	Analyst Forecast
NVAX Novavax	1.7323 of 5 stars	$10.39 +12.8%	$12.13 +16.7%	+48.4%	$1.71B	$1.12B	N/A	1,990	Analyst Upgrade Options Volume Analyst Revision
ABBV AbbVie	4.8318 of 5 stars	$212.37 -1.5%	$253.43 +19.3%	+17.4%	$375.21B	$61.16B	104.62	57,000	Trending News Analyst Upgrade
AZN Astrazeneca	3.9149 of 5 stars	$187.15 +0.1%	$205.33 +9.7%	+27.4%	$290.25B	$58.74B	28.10	96,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JNJ) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

How does Johnson & Johnson compare to Moderna?

Summary

How does Johnson & Johnson compare to Novavax?

Summary

How does Johnson & Johnson compare to AbbVie?

Summary

How does Johnson & Johnson compare to Astrazeneca?

Summary

How does Johnson & Johnson compare to Berkshire Hathaway?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

How does Johnson & Johnson compare to Moderna?

Does the media prefer MRNA or JNJ?

Do institutionals & insiders hold more shares of MRNA or JNJ?

Which has more volatility & risk, MRNA or JNJ?

Is MRNA or JNJ more profitable?

Which has better earnings & valuation, MRNA or JNJ?

Do analysts rate MRNA or JNJ?

Summary

How does Johnson & Johnson compare to Novavax?

Do analysts rate JNJ or NVAX?

Which has stronger earnings and valuation, JNJ or NVAX?

Does the media favor JNJ or NVAX?

Is JNJ or NVAX more profitable?

Which has more risk and volatility, JNJ or NVAX?

Do insiders & institutionals hold more shares of JNJ or NVAX?

Summary

How does Johnson & Johnson compare to AbbVie?

Does the media favor JNJ or ABBV?

Do analysts prefer JNJ or ABBV?

Is JNJ or ABBV more profitable?

Do institutionals and insiders believe in JNJ or ABBV?

Is JNJ or ABBV a better dividend stock?

Which has more volatility and risk, JNJ or ABBV?

Which has higher valuation and earnings, JNJ or ABBV?

Summary

How does Johnson & Johnson compare to Astrazeneca?

Which has more volatility and risk, JNJ or AZN?

Is JNJ or AZN more profitable?

Do insiders & institutionals have more ownership in JNJ or AZN?

Is JNJ or AZN a better dividend stock?

Which has stronger valuation & earnings, JNJ or AZN?

Does the media prefer JNJ or AZN?

Do analysts rate JNJ or AZN?

Summary

How does Johnson & Johnson compare to Berkshire Hathaway?

Do analysts prefer BRK.B or JNJ?

Do institutionals & insiders have more ownership in BRK.B or JNJ?

Does the media prefer BRK.B or JNJ?

Is BRK.B or JNJ more profitable?

Which has more risk and volatility, BRK.B or JNJ?

Which has higher earnings & valuation, BRK.B or JNJ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools